IRTC (IRTC) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving IRTC (IRTC) right now is Zio volume growth and category leadership: The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. Revenue (TTM) is ~$790M. If that keeps playing out, the setup is favourable; the risk to it is regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. No one can predict where IRTC trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive IRTC (IRTC) higher?
1. Zio volume growth and category leadership
The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. Q1 2026 revenue rose about 26% year over year to roughly $199 million, driven by sustained volume demand across the customer base. As the most widely prescribed ambulatory ECG monitor in the US, iRhythm benefits from installed physician habit and a large recurring stream of new patient prescriptions.
2. Next-generation Zio MCT and AI
iRhythm has submitted its next-generation Zio MCT (mobile cardiac telemetry) platform to the FDA and reaffirmed a first-half 2027 launch target for the AI-enabled version. MCT is a higher-acuity, real-time monitoring category that expands the addressable market beyond the mail-back patch. Deeper AI in the analysis pipeline is also positioned as a driver of both accuracy and margin over time.
3. Margin expansion toward profitability
Gross margin sits near 71% and the company turned adjusted-EBITDA positive, guiding to a full-year 2026 adjusted-EBITDA margin of roughly 12% to 13%. Operating leverage on a largely fixed analysis and sales infrastructure means incremental volume can flow through at high margins. The narrative has shifted from pure top-line growth toward a structural path to sustained profitability.
4. New markets and payer coverage
Growth catalysts include international expansion, deeper penetration in primary care and population health through risk-stratification partnerships, and adjacencies such as obstructive sleep apnea. US payer coverage now reaches about 93% of lives, reducing reimbursement friction for prescribers. These channels give iRhythm several independent levers to extend growth beyond its core cardiology base.
What could weigh on IRTC?
Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. The company still reports GAAP net losses and trades at a premium revenue multiple, so any volume slowdown, pricing pressure, or launch delay could compress the stock sharply. Competition from larger, better-capitalized players (Philips, Boston Scientific) and the possibility of equity issuance under a shelf registration add further risk. Investors should size positions with the understanding that medtech reimbursement and regulatory outcomes are difficult to predict.
Where IRTC trades today
A forecast starts from where the stock actually is. These are IRTC's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for IRTC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a IRTC forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the IRTC guide and whether IRTC is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the IRTC outlook
The bottom line: what is driving IRTC (IRTC) is Zio volume growth and category leadership, with revenue (ttm) at ~$790M. If that keeps playing out the setup is favourable; the risk is regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. No one can predict the price, so treat any IRTC forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around IRTC with Walnut
Use IRTC as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for IRTC (IRTC)?
+
No one can reliably predict where IRTC will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push IRTC higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive IRTC higher?
+
The main growth drivers are Zio volume growth and category leadership; Next-generation Zio MCT and AI; Margin expansion toward profitability. Whether they play out is the real question, not a guaranteed path.
What are the risks to IRTC?
+
Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. The company still reports GAAP net losses and trades at a premium revenue multiple, so any volume slowdown, pricing pressure, or launch delay could compress the stock sharply. Competition from larger, better-capitalized players (Philips, Boston Scientific) and the possibility of equity issuance under a shelf registration add further risk. Investors should size positions with the understanding that medtech reimbursement and regulatory outcomes are difficult to predict.
Will IRTC stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. IRTC's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is IRTC a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the IRTC "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is iRhythm growing?
+
Revenue grew about 26% year over year in Q1 2026 to roughly $199 million, and the company raised full-year 2026 guidance to about $875 million to $885 million, implying roughly 17% to 18% annual growth. Growth is driven by rising Zio prescription volumes and expanding payer coverage.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.